SCHEMBL3925046

SCHEMBL3925046

CC(C)(Cc1cccc(C(=O)NCCc2cccc(F)c2)c1)NCC(O[Si](C)(C)C(C)(C)C)c1cc(O)cc(O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ GAA P10253 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ SNCA P37840 2/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ SLC7A5 Q01650 1/20 0.35
▸ TP53BP1 Q12888 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ ADRB2 P07550 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13840626 1.00 PARP1 (0.41) PARP1LMNAGAAOPRM1OPRD1
SCHEMBL13840618 0.89 PARP1 (0.42) PARP1LMNAGAASNCANPC1
SCHEMBL3917123 0.89 PARP1 (0.42) PARP1LMNAGAASNCANPC1
SCHEMBL4387621 0.88 ADRB2 (0.47) PARP1LMNAGAASNCANAMPT
SCHEMBL4387615 0.88 ADRB2 (0.47) PARP1LMNAGAASNCANAMPT
SCHEMBL13840701 0.85 PARP1 (0.44) PARP1LMNAGAAOPRM1OPRD1
SCHEMBL3924678 0.85 PARP1 (0.44) PARP1LMNAGAAOPRM1OPRD1
SCHEMBL13840617 0.84 ADRB2 (0.47) RAB9AADRB2ADRB1
SCHEMBL3913906 0.84 ADRB2 (0.47) RAB9AADRB2ADRB1
SCHEMBL13840627 0.84 ADRB2 (0.39) ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730141-B1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2009-05-27 — — EP disclosed
US-7538141-B2 Compounds for the treatment of diseases PFIZER INC. 2009-05-26 — — US disclosed
EP-1730141-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-12-13 — — EP disclosed
US-20050222128-A1 Compounds for the treatment of diseases PFIZER INC 2005-10-06 — — US disclosed
WO-2005092887-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222128-A1 Compounds for the treatment of diseases LTC4S, LTB4R2, CYP11B2 PARP1 2533/4885LMNA 1540/4885GAA 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback